Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) increased 8.18% yesterday. This is why it happened.

TNXP Stock Price Increased 8.18%: Why It Happened

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said in a regulatory filing that plans are underway to construct a commercial-scale manufacturing site to develop and manufacture vaccines, including its experimental COVID-19 shot, TNX-1800. The Montana facility intended to develop and manufacture Tonix's vaccine candidates will be a “public/private sector collaboration between Ravalli County and Tonix Pharmaceuticals that will bring more high-tech bioscience jobs to the Bitterroot Valley,” the company said.

Tonix Pharma Stock Moving Higher On Plans For Vaccine Manufacturing Facility In Bitterroot Valley

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC1).  Tonix plans to meet the FDA in Q3 of 2021 to seek agreement on designing a potential Phase 2 study and the overall clinical development plan.

Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome

Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m. ET.

Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102 SL tablet for the management of fibromyalgia. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues.

Tonix Pharma Fibromyalgia Treatment Associated with Improvement in Pain, Sleep, Fatigue

BioCryst Pharmaceuticals

Shares of these biotechs have been soaring in the opposite direction of their peers.

2 Biotech Stocks Bucking the Trend Right Now

Lots of irons in the fire could be distracting investors from the most serious problem this company faces right now.

1 Huge Warning Sign in Tonix Pharmaceuticals' Earnings

CHATHAM, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the Q2 Investor Summit Virtual Conference on Monday, May 17, 2021 at 3:30 p.m. ET.

Tonix Pharmaceuticals to Present at May Investor Summit Virtual Conference

Announced Positive Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800

Tonix Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

This biotech's ambitious development pipeline keeps attracting attention.

Could Tonix Pharmaceuticals Be a Millionaire-Maker Stock?

Tonix Pharma: Interesting Molecule In Fibromyalgia, But Generic Availability Is A Concern

CHATHAM, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, was invited to deliver a company presentation and participate in a panel at the 4th Annual Neuroscience Innovation Forum for Business Development, Licensing and Investment, hosted by Sachs Associates and taking place from April 28-30, 2021.

Tonix Pharmaceuticals to Participate in Fourth Annual Neuroscience Innovation Forum

There is a good chance Tonix Pharmaceuticals (NASDAQ:TNXP) breaks the support at $1 and moves lower. There's support at this level because it's important psychologically.

Is Tonix Pharmaceuticals About To Breakdown?

Toughbuilt Industries Inc

Torchlight Energy Resources

22nd Century Group

Finding trending penny stocks can be a great place to start making a watchlist; here's 3 to consider The post 4 Trending Penny Stocks to Watch on Monday, April 19th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Trending Penny Stocks to Watch on Monday, April 19th

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased by over 19% during intraday trading. This is why it happened.

TNXP Stock: Over 19% Increase Intraday Explanation

TNXP stock is up today with news that the company is joining with a biotech company to commercialize a new coronavirus therapy. The post TNXP Stock: The Huge Covid-19 News Boosting Tonix Pharmaceuticals Today appeared first on InvestorPlace.

TNXP Stock: The Huge Covid-19 News Boosting Tonix Pharmaceuticals Today

The company struck a deal to bolster its COVID-19 pipeline.

Why Tonix Pharmaceuticals Stock Is Jumping Today

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders. Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19.

Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact

Trevena

These high-risk, high-reward healthcare stocks have outperformed the market over the past year.

2 Best Reddit Healthcare Stocks to Buy Now

CHATHAM, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:00 a.m. ET.

Tonix Pharmaceuticals to Present at Needham Virtual Healthcare Conference

Company Expects to Initiate a Phase 2 Clinical Trial in the Fourth Quarter of 2021, Pending Results of Toxicology Studies Company Expects to Initiate a Phase 2 Clinical Trial in the Fourth Quarter of 2021, Pending Results of Toxicology Studies

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder

The stock price of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) increased by over 5% pre-market. This is why it happened.

TNXP Stock Price Increases Over 5% Pre-Market: Why It Happened

CHATHAM, N.J., March 19, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,946,027 to the Company on March 16, 2021. Tianeptine oxalate is the active pharmaceutical ingredient of Tonix's development candidate, TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablet). The new patent, “Tianeptine Oxalate Salts and Polymorphs,” includes claims directed to pharmaceutical compositions comprising crystalline tianeptine oxalate salts, to methods of using those compositions to treat various disorders, and to methods of producing the oxalate salts. This patent is expected to provide Tonix with U.S. market exclusivity until December 28, 2037, excluding any patent term extensions.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR

American Resources Corp

Lipocine

Onconova Therapeutics

Zhongchao

Amid risk-on sentiment, penny stocks are surging higher today as investors seek to grab the higher upside these small-cap stocks provide. The post Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and ZCMD appeared first on InvestorPlace.

News for Tonix Pharmaceuticals Hld Stock (TNXP)